Navigation Links
Verinata Health Announces New Findings At The American Society Of Human Genetics
Date:11/9/2012

REDWOOD CITY, Calif., Nov. 9, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced two poster presentations at the 62nd Annual Meeting of the American Society of Human Genetics (ASHG). The conference is being held in San Francisco, California.

(Logo: http://photos.prnewswire.com/prnh/20120425/SF94380LOGO)

"The verifi® prenatal test offers pregnant women access to a blood test that is safe, early and accurate," said Dr. Jeffrey Bird, Executive Chairman and CEO of Verinata Health.  "Looking beyond our current product offering, our early work presented at ASHG represents an exciting possibility for future non-invasive prenatal tests. While this initial work serves as a proof of principal, it clearly demonstrates the power and potential of massively parallel sequencing to detect alterations within individual chromosomes, similar to chromosomal microarrays."

The following posters were presented at ASHG on Thursday, November 8, 2012:

  • Detection of Fetal Sub-Chromosomal Alterations in Maternal Plasma Cell-Free DNA (cfDNA) Using Massively Parallel Sequencing (MPS). (Poster #3021T) This poster demonstrates that Verinata's proprietary technology, together with next-generation sequencing, can be used to detect subchromosomal changes in the fetus.
  • cfDNA is not Compromised by Temperature Stress of Maternal Blood Collected in Streck Cell-Free DNA BCT. (Poster #3007T)

About the verifi® prenatal test
The verifi® prenatal test is a blood test that analyzes genetic material (or DNA) naturally found in a pregnant woman's blood to detect the most common fetal chromosome abnormalities.  When directed by a physician, the verifi test can be offered to pregnant women of at least 10 weeks gestation at high risk of carrying a fetus with a genetic abnormality. A physician may classify a woman as "high-risk" if she is over 35 years of age, has a prior personal or family history of chromosome abnormalities, or has had a positive initial screening test indicating she is at increased risk for carrying a fetus with a genetic abnormality.

Verinata Health, Inc.
Verinata is driven by a sole, extraordinary purpose – maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies. We aim to reduce the anxiety associated with today's multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result. The verifi® prenatal test is available throughout the United States, with the exception of New York, through a physician. For more information about Verinata, please go to www.verinata.com.


'/>"/>
SOURCE Verinata Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Genomic Health to Present at Two Upcoming Investor Conferences
2. Baylor University scientist receives major grants for health research on 1991 Gulf War veterans
3. Obese dogs at risk of health condition experienced by humans
4. Obese moms give birth to heart healthier kids following bariatric surgery
5. New Study Shows That Improvements in Employee Health Behaviors Persist Over Two Years
6. US investment in biomedical and health research on downward trend
7. Omega-3 intake heightens working memory in healthy young adults
8. Pigs look healthy but test positive for flu at fairs; transmission seen between pigs and humans
9. INTEGRIS Health Puts Patient Safety in the Palm of Your Hand
10. Study: DNA barcoding can ID natural health products
11. App lets you monitor lung health using only a smartphone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):
(Date:6/23/2017)... Washington, USA, and CARDIFF, UK (PRWEB) , ... June 23, 2017 ... ... Lab (LANL), and Brian Lula, president of Physik Instrumente USA, have been selected as ... optics and photonics . , The two have been invited along with other honorees ...
(Date:6/22/2017)... ... , ... Building on the success of the inaugural RAADfest last year, RAADfest ... developments in radical life extension. RAADfest combines cutting edge science presented for a lay ... development, making it the largest most comprehensive and inclusive super longevity event in the ...
(Date:6/22/2017)... ... ... The first human cell line HeLa, established in 1951, has entered cell ... human cell lines with HeLa cells were published. Until recently, cross-contamination and misidentification of ... associated with dramatic consequences for research. , In this educational webinar, which is ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... to immediately determine the adulterants which pose the most likely threat to their ... 28 of this year. , IFT's annual food expo attracts over 20,000 ...
Breaking Biology Technology: